Abstract
Drug screening, that is, the evaluation of the biological activity of candidate drug molecules, is a key step in the drug discovery and development process. In recent years, high-throughput screening assays have become indispensable for early stage drug discovery because of the developments in synthesis technologies, such as combinatorial chemistry and automated synthesis, and the discovery of an increasing number of new pharmacological targets.
Bioluminescence and chemiluminescence represent suitable detection techniques for high-throughput screening because they allow rapid and sensitive detection of the analytes and can be applied to small-volume samples. In this paper we report on recent applications of bioluminescence and chemiluminescence in drug screening, both for in vitro and in vivo assays. Particular attention is devoted to the latest and most innovative bioluminescence and chemiluminescence-based technologies for drug screening, such as assays based on genetically modified cells, bioluminescence resonance energy transfer (BRET)-based assays, and in vivo imaging assays using transgenic animals or bioluminescent markers. The possible relevance of bioluminescence and chemiluminescence techniques in the future developments of high-throughput screening technologies is also discussed.
Similar content being viewed by others
References
Garcia-Campana AM, Baeyens WRG (2001) (eds) Chemiluminescence in analytical chemistry. Marcel Dekker, New York
Van Dyke K, Van Dyke C, Woodfork K (2002) (eds) Luminescence biotechnology: instruments and applications. CRC Press, Boca Raton
Campbell AK (1988) Chemiluminescence: principles and applications in biology and medicine. VCH, Cambridge, chap 5
Lehel C, Daniel-Issakani S, Brasseur M, Strulovici B (1997) Anal Biochem 244:340–346
Ross H, Armstrong CG, Cohen P (2002) Biochem J 366:977–981
Maurer TS, Fung H (2000) Nitric Oxide 4:372–278
Andreani A, Cavalli A, Granaiola M, Guardigli M, Leoni A, Locatelli A, Morigi R, Rambaldi M, Recanatini M, Roda A (2001) J Med Chem 44:4011–4014
Forghani F, Ouellet M, Keen S, Percival MD (1998) Anal Biochem 264:216–221
Roda A, Russo C, Pasini P, Piazza F, Feroci G, Kricka LJ, Baraldini M (1998) J Biolumin Chemilumin 13:327–337
Deo SK, Lewis JC, Daunert S (2000) Anal Biochem 281:87–94
Mirasoli M, Pasini P, Russo C, Lotierzo M, Valenti P, Guardigli M, Roda A. In Roda A, Pazzagli M, Kricka LJ, Stanley PE (1999) (eds) Bioluminescence and chemiluminescence: perspectives for the 21st century. Wiley, Chichester, pp 524–527
Ogawa A, Arai H, Tanaziwa H, Miyahara T, Toyo'oka T (1999) Anal Chim Acta 383:221–230
Salles B, Sattler U, Bozzato C, Calsou P (1999) Food Chem Toxicol 37:1009–1014
Joyeux A, Balaguer P, Germain P, Boussioux AM, Pons M, Nicolas JC (1997) Anal Biochem 249:119–130
Naylor LH (1999) Biochem Pharmacol 58:749–757
Deo SK, Daunert S (2001) Fresenius J Anal Chem 369:258–266
Terouanne B, Tahiri B, Georget V, Belon C, Poujol N, Avances C, Orio F Jr, Balaguer P, Sultan C (2000) Mol Cell Endocrinol 160:39–49
Blankvoort BM, de Groene EM, van Meeteren-Kreikamp AP, Witkamp RF, Rodenburg RJ, Aarts JM (2001) Anal Biochem 298:93–102
Beckers T, Reilander H, Hilgard P (1997) Anal Biochem 251:17–23
Conway S, Canning SJ, Howell HE, Mowat ES, Barrett P, Drew JE, Delagrange P, Lesieur D, Morgan PJ (2000) Eur J Pharmacol 390:15–24
Terstappen GC, Giacometti A, Ballini E, Aldegheri L (2000) J Biomol Screen 5:255–262
Goetz AS, Andrews JL, Littleton TR, Ignar DM (2000) J Biomol Screen 5:377–84
Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, Hull MV, Lustig KD, Mangelsdorf DJ, Shan B (1999) Science 284:1362–5
Repa JJ, Mangelsdorf DJ (2000) Annu Rev Cell Dev Biol 16:459–81
Postlind H, Vu TP, Tukey RH, Quattrochi LC (1993) Toxicol Appl Pharmacol 118:255–262
Boute N, Pernet K, Issad T (2001) Mol Pharmacol 60:640–645
Issad T, Boute N, Pernet K (2002) Biochem Pharmacol 64:813–817
Rios CD, Jordan BA, Gomes I, Devi LA (2001) Pharmacol Ther 92:71–87
Angers S, Salahpour A, Joly E, Hilairet S, Chelsky D, Dennis M, Bouvier M (2000) Proc Natl Acad Sci USA 97:3684–9
Boute N, Jockers R, Issad T (2002) Trends Pharmacol Sci 23:351–354
Contag PR (2002) Drug Discov Today 7:555–562
Francis KP, Joh D, Bellinger-Kawahara C, Hawkinson MJ, Purchio TF, Contag PR (2000) Infect Immun 68:3594–3600
Sweeney TJ, Mailänder V, Tucker AA, Olomu AB, Zhang W, Cao Y, Negrin RS, Contag CH (1999) PNAS 96:12044–12049
Contag CH, Jenkins D, Contag PR, Negrin RS (2000) Neoplasia 2:41–52
Laxman B, Hall DE, Swaroop Bhojani M, Hamstra DA, Chenevert TL, Ross BD, Rehemtulla A (2002) PNAS 99:16551–16555
Paulmurugan R, Umezawa Y, Gambhir SS (2002) PNAS 99:15608–15613
O'Connell-Rodwell CE, Burns SM, Bachmann MH, Contag CH (2002) Trends Biotechnol 20:S19-S23
Contag CH, Contag PR (1999) Chem Ind 6:664–666
Rocchetta HL, Boylan CJ, Foley JW, Iversen PW, LeTourneau DL, McMillian CL, Contag PR, Jenkins DE, Parr TR Jr (2001) Antimicrob Agents Chemother 45:129–137
Templin MF, Stoll D, Schrenk M, Traub PC, Vöhringer CF, Thomas OJ (2002) Trends Biotechnol 20:160–166
MacBeath G, Koehler AN, Schreiber SL (1999) J Am Chem Soc 121:7967–7968
Weigl HB, Bardell RL, Cabrera CR (2003) Adv Drug Deliver Rev 55:349–377
Kanigan T, Brenan C, Lafontaine S, Soswoski L, Madden P, Hunter I (2000) SPIE Proceedings, 3926, pp. 172–180
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Roda, A., Guardigli, M., Pasini, P. et al. Bioluminescence and chemiluminescence in drug screening. Anal Bioanal Chem 377, 826–833 (2003). https://doi.org/10.1007/s00216-003-2096-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00216-003-2096-6